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ABSTRACT 
Radiation therapy is an important local cytotoxic modality for cancer treatment whose aim is to control the disease 
while minimising damage to normal tissue. The combination of different treatment modalities offers a more effective 
cure and reduction in normal tissue toxicity. However, the differences in genetic profiles can cause diverse treatment 
outcomes.  Multidisciplinary  research,  where  technologies  and  knowledge  from  different  areas  are  integrated,  is 
necessary to design the optimal regimen for individualised cancer treatment. This paper offers an overview of some new 
cancer treatment strategies; the impact of molecular imaging on radiation oncology; and a computer simulation model to 
optimise  treatment  planning  based  on  patient  information.  It  briefly  discusses  molecular  targeted  therapy,  tumour 
microenvironment and bioreductive agents, and evidence for making individualised medicine a reality. Using DNA 
microarrays and proteomic technologies, information on defined molecular targets and genetic profiling for individual 
patients can be obtained and new algorithms for radiation oncology-related diagnosis, treatment response and prognosis 
can be developed. © 2006 Biomedical Imaging and Intervention Journal. All rights reserved. 
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INTRODUCTION 
The  treatment  of  cancer  currently  uses  different 
modalities,  either  alone  or  in  combination,  for  more 
effective  cures  and  to  avoid  unwanted  effects. 
Experimental and theoretical studies in radiation biology 
and  other  related  fields  have  substantially  grown  to 
improve the field of radiotherapy which has undergone a 
marked development as a consequence of new biological 
and technological knowledge and abilities. 
Different cancers behave and respond to treatment 
differently.  Therefore,  we  need  to  understand  the 
molecules  involved  and  their  functions,  such  as 
intracellular  and  intercellular  signalling  cascades  that 
regulate  radiation  sensitivity  and  resistance  of  both 
tumour  and  normal  cells.  As  basic  molecular  biology 
techniques have been progressing rapidly and the human 
genome project has completed mapping and sequencing 
all  the  genes  in  humans,  the  information  gained  will 
greatly impact cancer treatment. 
Individualised cancer treatment, which is the goal of 
the  next  revolution  in  radiation  oncology,  can  be 
achieved with intense approaches into the field of DNA 
repair,  cell  cycle  control  and  signalling  transduction, 
tumour  microenvironment  and  molecular  targeting  in 
radiation oncology.   
Present  address:  Division  of  Therapeutic  Radiology  and  Oncology, 
Faculty of Medicine, ChiangMai University, Thailand. Tel: +66 5394 
5456;  Fax:  +66  5394  5491;  E-mail:  nchawapu@mail.med.cmu.ac.th
(Nisa Chawapun). N. Chawapun. Biomed Imaging Interv J 2006; 2(1):e22    2 
    This page number is not 
    for citation purpose 
MOLECULAR TARGETING IN RADIATION ONCOLOGY 
Targeted therapy is a medication or chemical that 
targets  a  specific  pathway  in  the  growth  and 
development  of  cancer.  There  are  several  classes  of 
targeted  therapies  [1]  such  as  tyrosine  kinase  receptor 
inhibitors, angiogenesis inhibitors, proteosome inhibitors, 
and immunotherapy. 
Tyrosine kinase receptor inhibitors 
Cell  growth  in  normal  tissue  is  controlled  by 
balancing  growth-promoting  and  growth-inhibiting 
factors. When the balance in malignant tumour cells is 
disturbed, the cells can proliferate without control. A key 
driver for growth is the epidermal growth factor (EGF) 
and  its  receptor  [epidermal  growth  factor  receptor 
(EGFR)].  EGFR  is  a  member  of  a  family  of  four 
receptors, i.e., EGFR (HER1/ErbB1), ErbB2 (HER2/neu), 
ErbB3 (HER3), and ErbB4 (HER4). These proteins are 
located  in  the  cell  membrane  and  each  has  a  specific 
external ligand binding domain, a helical transmembrane 
domain, and an intracellular domain with tyrosine kinase 
enzyme  activity  [2,3].  As  shown  in  Figure  1,  the 
extracellular part contains two cysteine-rich domains that 
can bind a number of growth factors [2]. Activation of 
EGFR following the growth factor (ligand) binding leads 
to homodimerisation of the receptor with another EGFR, 
or heterodimerisation with another member of the EGFR 
family.  Receptor  dimerisation  initiates  a  signalling 
cascade  that  results  in  protection  from  apoptosis  and 
stimulation  of  cell  proliferation,  angiogenesis,  cell 
differentiation  and  cell  migration.  EGFR  intracellular 
signalling is mainly through two downstream pathways, 
the Ras-Raf-mitogen-activated protein kinases (MAPK) 
and  the  phosphatidylinositol  3-kinase  (PI3K)/Akt 
pathways [2,3]. The quick-time animation of EGFR and 
its signalling cascade are available online [4].  
The EGFR gene is a protooncogene and plays a key 
role  in  the  development  of  human  tumours.  EGFR 
activation occurs due to EGFR gene amplification, gene 
mutation,  or  through  growth  factor  overproduction. 
EGFR  status  can  be  determined  by  measuring  protein 
expression,  mRNA  expression,  gene  amplification  or 
gene  mutation,  but  the  most  widely  used  assay  is 
immunohistochemistry that measures protein expression 
[3]. 
The  reasons  for  targeting  EGFR  in  anticancer 
therapy are: the importance of EGFR signalling in the 
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development of tumours; the association between EGFR 
overexpression and poor prognosis in many cancers; and 
the  distinct  mechanism  of  action  of  anti-EGFR 
approaches versus conventional methods. Currently, two 
approaches are in clinical development and clinical trials: 
the  use  of  monoclonal  antibodies  (mAbs)  directed 
against  the  external  domain  of  the  receptor,  e.g., 
cetuximab, ABX-EGF, EMD72000; and the use of small 
molecule inhibitors of EGFR tyrosine kinase enzyme that 
competes with the ATP binding site of the intracellular 
domain of the EGFR and blocks intracellular signalling, 
e.g., ZD1839, OSI-774, CI-1033, EKB-569, GW572016 
[5]. Trastuzumab or NO34 is the monoclonal antibody 
inhibitor for another family member, HER2/neu, that is 
used  in  breast  cancer  with  overexpression  of  HER2 
protein. 
Other  approaches  in  pre-clinical  development  for 
targeting EGFR are: anti-sense oligonucleotides, EGFR-
directed vaccines, and immunoconjugates of antibodies 
coupled to a radioactive isotope or cytotoxin [3]. It is, 
therefore, classified as immunotherapy. Pre-clinical and 
clinical studies have shown that different inhibitors have 
in-vitro and in-vivo activity that potentiates the effects of 
cytotoxic agents and radiation. The addition of ZD1839 
to cisplatin-5FU affects signalling pathways that control 
cell proliferation, apoptosis and DNA repair in human 
head and neck cancers’ cell lines [6]. Caspase-3 activity 
was increased in the drug combination exposure, while 
ZD1839 alone induced G0/G1 arrest accompanied by an 
increase in G1 cell cycle regulator, p21 and p27, and Bax; 
and a decrease in Bcl-2, Akt phosphorylation and DNA-
PK.  The  study  on  human  breast  cancer  cell  lines  also 
showed  a  synergistic  interaction  between  ZD1839  and 
chemotherapeutic agents in anti-proliferative action and 
the delayed repair of DNA damage [7]. The enhancement 
of tumour radioresponse through the modulation of DNA 
repair was reported [8,9].  
The  literature  review  on  the  role  of  EGFR-TK 
signalling  in  tumour  response  to  radiation  therapy 
indicates that EGFR-TK activity in tumours can block 
the  cytotoxic  effects  of  radiation  therapy  and  enhance 
tumour  repopulation,  resulting  in  the  failure  of  local 
tumour control [10]. Combining ZD1839 with radiation 
therapy  can  improve  responses  in  non-small  cell  lung 
cancer, head and neck cancers, and other solid tumours. 
It  has  been  hypothesised  that  exposure  to  ionising 
radiation activates the EGFR and subsequently activates 
the  downstream  signalling  pathway  involving  the 
protective  stress  response.  The  treatment  with  the 
tyrosine  kinase  inhibitor  can  prevent  radiation-induced 
EGFR autophosphorilation. Clinical studies reveal that it 
is  the  mutations  within  the  EGFR-TK  domain  that 
predict the response to the EGFR inhibitor; not the level 
of  tumour  EGFR  expression  [11].  Further  studies  are 
required  to  identify  patients  who  are  likely  to  benefit 
from this therapy. 
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Angiogenesis inhibitors  
Angiogenesis is the formation of a new blood vessel 
from  an  existing  vasculature.  It  occurs  infrequently  in 
normal  adults,  except  during  times  of  wound  healing, 
inflammation, ovulation, pregnancy or ischemia. Tumour 
angiogenesis is the proliferation of a network of blood 
vessels that penetrates into cancerous growths, supplying 
nutrients  and  oxygen,  and  removing  waste  products. 
Angiogenesis  is  regulated  by  activator  and  inhibitor 
molecules, which activate certain genes in the host tissue 
[12].  Figure  2  illustrates  the  angiogenesis  signalling 
cascade.  The  two  most  important  angiogenesis-
stimulating molecules, vascular endothelial growth factor 
(VEGF) and basic fibroblast growth factor (bFGF), are 
released by tumour cells into the surrounding tissue. The 
binding of the factor to its receptor at an endothelial cell 
surface activates the signalling pathway, leading to new 
endothelial cell growth. To form the new blood vessels, 
the  activated  endothelial  cells  produce  the  degradative 
enzymes, matrix metalloproteinases (MMPs), which are 
then released into the surrounding tissue to break down 
the  extracellular  matrix.  This  enables  the  endothelial 
cells  to  migrate,  divide  and  then  organise  to  form  a 
network  of  blood  vessels.  Cells  transformed  by  RAS, 
MYC,  RAF,  c-erbB-2,  c-JUN  or  SRC  have  a  strong 
angiogenic phenotype, either through the up-regulation 
of pro-angiogenic factors or reciprocal down-regulation 
of  anti-angiogenic  factors.  It  has  been  postulated  that 
inhibiting  angiogenesis  can  slow  down  or  prevent  the 
growth of cancer cells. The naturally occuring proteins 
that inhibit angiogenesis are angiostatin, endostatin and 
thrombospondin.  Angiogenesis  inhibitors  can  be 
categorised  by  their  mechanism  of  action.  The  first 
category  includes  molecules  that  inhibit  angiogenesis 
directly  by  inhibiting  endothelial  cell  function, 
promoting apoptosis of endothelial cells, or interacting 
with integrin to promote the destruction of proliferating 
endothelial  cells.  The  second  category  consists  of 
molecules that block the angiogenesis signalling cascade 
and  includes  drugs  that  interfere  with  endothelial  cell 
receptors  or  inhibit  the  production  of  pro-angiogenic 
factors. The third category includes molecules that block 
the breakdown of the extracellular matrix by inhibiting 
the  activity  of  MMPs.  The  last  category  consists  of 
inhibitors that involve, either a non-specific mechanism 
of actions or mechanisms that are not clearly understood. 
Table 1 shows some of the angiogenesis inhibitors that 
are being tested in cancer patients.  
Information on the status of anti-angiogenic clinical 
trials  can  be  accessed  at  the  National  Cancer  Institute 
website (http://www.cancer.gov/clinicaltrials/digestpage/ 
angiogenesis-inhibitors).  AEE788,  a  potent  combined 
inhibitor of both EGF and VEGF receptor and a tyrosine 
kinase family member, is in Phase I clinical trials as it 
inhibits  EGFR/ErbB2  phosphorylation-mediated 
proliferation  in  in-vitro  studies  and  demonstrates  anti-
angiogenic effects in a VEGF-driven animal model [14]. 
Table 1 The angiogenesis inhibitors that are being tested in cancer patients. 
Category  Mode of action  Drug(s) 





Causes apoptosis of endothelial cells  Combretastatin 4 
Inhibit angiogenesis directly 
Promotes the destruction of proliferating 
endothelial cells by interacting with integrin 
Medi-522 
 
Inhibits the production of bFGF and VEGF  Interferon-alpha 
Block the angiogenesis signalling 







Block extracellular matrix 






Inhibits calcium uptake  CAI 
Up-regulates interferon-gamma and IP-10  Interleukin-12 
Non-specific mechanism of 
action 
Unknown  IM862 
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Proteosome inhibitors 
Proteosome  or  a  protein  shredder  is  an  enzyme 
complex in the cell, which is responsible for breaking 
down proteins. Many different proteins are destroyed by 
the  proteosome  when  they  are  no  longer  needed, 
including  signalling  proteins,  enzymes  and  structural 
proteins [15]. Disruption of this system can transform the 
cell.  The  important  proteins  that  are  substrates  of 
proteosome include the inhibitor of nuclear factor kappa 
B  (NF-κB;IκB),  p53  tumour  suppressor,  the  cyclin-
dependent  kinase  inhibitors  p21  and  p27,  and  the 
proapoptotic protein Bax [16]. The molecular targets of 
proteosome  inhibitors  and  their  contribution  to  anti-
tumour  effect  are  summarised  in  Table  2.  Proteosome 
inhibitors induce apoptosis, reverse drug resistance and 
affect  the  cell  microenvironment  by  blocking  cytokine 
circuits,  cell  adhesion  and  angiogenesis.  Phase  III 
clinical trials have been conducted for bortezomib, a new 
class of proteosome inhibitors, and the impressive result, 
as compared with high-dose dexamethasone in multiple 
myeloma treatment, was reported by the Assessment of 
Proteosome Inhibition for Extending Remission (APEX) 
group  [17].  However,  adverse  events,  i.e.,  peripheral 
neuropathy,  cerebrovascular  accident  and  grade  3 
abdominal pain, were reported in patients with metastatic 
colorectal cancer during Phase II trials of this drug [18]. 
Phase I and II trials of bortezomib, in combination with 
other agents, have been conducted. 
Immunotherapy 
In  targeted  immunotherapy,  the  inhibitors  bind  to 
their  targets.  This  does  not  interfere  with  the  growth 
signal, but triggers the immune signal leading to a series 
of anti-tumour immune reactions in the body, causing the 
destruction  of  the  tumour  cells.  The  dual  attack  on 
tumour  cells  can  be  achieved  by  using 
radioimmunotherapy agents. The immunotherapy drugs 
are  chemically  attached  to  the  radioactive  substances, 
taking  advantage  of  both  the  anti-tumour  immune 
response  and  anti-tumour  radiation  reaction.  Recently 
developed  approaches  in  this  field  are  classified  as 
strategies based on cytokines, dendritic cell, vaccination, 
and targeting toll-like receptor [19]. 
TUMOUR MICROENVIRONMENT 
Tumour microenvironment is the characterisation of 
the physiological and metabolic conditions within solid 
tumors,  whether  primary  or  metastatic  site.  In  most 
tumours, it shows low glucose concentration, high lactate 
concentration,  low  extracellular  pH  and  low  oxygen 
tensions [20]. The major factors causing tumour hypoxia 
(O2 tension ≤ 2.5 mm Hg) are abnormal structure and 
function  of  microvessels  supplying  tumours;  large 
diffusion  distances  between  blood  vessels  and  tumour 
cells; and low oxygen transport capacity of blood [21]. 
Besides  a  reduction  in  the  generation  of  free  radicals, 
which is the direct mechanism, the alterations in gene 
expression as well as the genetic instability induced by 
Table 2 Molecular targets of proteosome inhibitors [16] 
Target  Sequelae of proteosome inhibition  Contribution to anti tumour effect 
NFκB*  Stabilisation of IκB, which inhibits nuclear 
translocation of NFκB 
Decreases NFκB-dependent transcription of genes important in 
tumour cell survival, proliferation, invasion and metastasis, and 
angiogenesis 
p53   Accumulation of p53 protein by inhibition of 
proteosome-mediated p53 degradation 
Increases p53-dependent transcription of cell cycle inhibitors 
(p21) and proapoptotic factors (Bax) 
p21 and p27  Accumulation of both p21 and p27, and increased 
transcription of p21 through accumulation of p53 
Induces G1/S cell cycle arrest and apoptosis 
Bax  Accumulation of Bax by inhibition of proteosome 
mediated Bax degradation and through increased p53-
mediated transcription 
Increases Bax interaction with Bcl-2 and Bcl-xL, promoting 
release of mitochondrial cytochrome cand apoptosis 
p44/42MAPK   Transcriptional activation of the MKP-1 phosphatase, 
leading to p44/42 dephosphorylation andinactivation 
Down-regulates p44/42-dependent cell proliferation and survival 
signals, and possibly angiogenesis 
tBid   Accumulation through decreased proteosomal 
degradation 
tBid induces conformational changes in Bak, promoting 
mitochondrial release of cytochrome c 
Smac/Diablo   Accumulation through decreased proteosomal 
degradation 
Smac and Diablo bind to and inhibit members of the XIAP protein 
family 
* NFκB, nuclear factor κB; IκB, inhibitor of nuclear factor κB; MAPK, mitogen activated protein kinase; 
Diablo, direct IAP binding protein with low pI; Smac, Second mitochondria-derived activator of caspase; XIAP, 
X-chromosome-linked inhibitor of apoptosis. 
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hypoxia may increase resistance to therapy and add to 
the development of a more aggressive tumour phenotype 
[22]. Hypoxia-induced alterations in gene expression are 
controlled by a number of oxygen-regulated transcription 
factors, among which hypoxia-inducible factor 1 (HIF-1) 
and nuclear factor kappa B (NF-κB) dependent pathways 
are important. Two main strategies to overcome tumour 
hypoxia  are  to  increase  the  delivery  of  oxygen  or  use 
oxygen-mimetic drug, and to exploit the environmental 
condition  for  targeted  therapy  [23].  The  use  of 
hyperbaric oxygen, electron-affinic radiosensitisers and 
nitroimidazole  compound  comprises  the  first  strategy, 
while the use of bioreductive drugs and hypoxia-targeted 
suicide gene therapy leads to activated cytotoxic agents 
specifically at the tumour site. As patient compliance is a 
problem, only some nitroimidazole compounds such as 
nimorazole  were  reported  to  significantly  improve  the 
effect of radiotherapy in supraglottic, larynx and pharynx 
carcinomas  [24].  The  latter  class  of  anti-tumour  pro-
drugs exploits the ability of solid cancers to carry out 
reductive  metabolism,  leading  to  the  production  of  a 
cytotoxic  species  which  can  then  damage  and  kill  the 
malignant cells. [25] The rationale for clinical use is that 
the  bioreductive  metabolism  reaction,  especially  when 
catalyzed by one-electron reductases, is oxygen sensitive 
– only occurring in the absence of oxygen. Therefore, 
bioreductive drug activation is favoured in many solid 
cancers  containing  hypoxic  tumour  cells  because  of  
insufficient  and  aberrant  vasculature.  Numerous 
compounds  are  currently  at  various  stages  of  drug 
development,  but  mitomycin  C  and  tirapazamine  have 
been  impressive  in  the  clinic.  Tirapazamine  (1,2,4-
benzotriazin-3-amine 1, 4-dioxide) becomes activated by 
NADPH:  cytochrome  450  reductase  to  give  cytotoxic 
metabolites.  The  suggested  mechanism  of  action  of 
tirapazamine is DNA strand break. 
Radiosensitisation, through improvements in tumour 
oxygenation/hypoxic  cell  sensitisation,  has  limited 
success through the use of hyperbaric oxygen, electron-
affinic radiosensitisers, and mitomycin. Phase I, II and 
III trials with tirapazamine in combination with cisplatin 
for the treatment of solid tumours, including non-small 
cell  lung  cancer,  breast  cancer,  head  and  neck  cancer, 
and melanoma, have been conducted. Tirapazamine as an 
adjuvant  to  radiotherapy  for  head  and  neck  cancer, 
cervical cancer and glioblastoma multiforme is in Phase 
II trials. 
IMPACT OF MOLECULAR IMAGING ON RADIATION 
ONCOLOGY 
Molecular  imaging  has  two  basic  applications: 
diagnostic imaging, to determine the location and extent 
of  targeted  molecules;  and  therapy,  to  treat  specific 
disease-target molecules  by  adding  a  therapeutic  agent 
onto the probe. 
In the last decade, substantial technological progress 
has  led  to  major  developments  in  radiation  oncology. 
The  new  algorithms  for  three-dimensional 
reconstructions of anatomy and dose calculation enable 
the delivery of radiation treatment with high geometric 
precision,  i.e.,  stereotactic  radiotherapy  (SRT), 
stereotactic radiosurgery (SRS), and intensity-modulated 
radiotherapy (IMRT). Therefore, more accurate tumour 
identification  and  delineation  are  required.  The 
International  Commission  on  Radiation  Units  and 
Measurement  (ICRU)  defines  the  concept  of  target 
volume for radiation treatment as: gross tumour volume 
(GTV), the volume that includes the demonstrable extent 
and  location  of  the  primary  tumour,  regional  lymph 
nodes  and  distant  metastases;  clinical  target  volume 
(CTV), the volume that includes GTV and/or subclinical 
disease; and planning target volume (PTV) that includes 
any geometric uncertainties and set up margins [26]. The 
target volume definition is currently based on computed 
tomography  (CT)  and  magnetic  resonance  imaging 
(MRI). The information obtained is only morphological. 
However,  in  recent  years,  new  methods  for  tumour 
visualisation  have  begun  to  impact  radiation  oncology 
[27,28].  Techniques  such  as  positron  emission 
tomography  (PET),  single-photon  emission  computed 
tomography  (SPECT)  and  magnetic  resonance 
spectroscopy  (MRS)  permit  the  visualisation  of 
biological  pathways  of  tumours  and  offer  additional 
information about metabolism, physiology and molecular 
biology  of  tumour  tissue.  This  new  class  of  images, 
showing  specific  biological  events,  complements  the 
anatomic  information  from  traditional  radiological 
techniques. The most popular PET tracer is fluorine-18 
fluorodeoxyglucose (FDG). FDG is a glucose analog that 
is transported into cells on the gluc-1 transporter. Gluc-1 
is overexpressed in cancer and responsible for the high 
accumulation of F-18 FDG in metastatic cells. FDG is 
phosphorylated by hexokinase after entering the cell and 
trapped  inside  by  the  change  in  electrical  charge. 
Another  tracer  is  a  thymidine  derivative,  F-18 
fluorodeoxythymidine (FLT), that is phosphorylated by 
TK-1,  an  enzyme  that  is  highly  expressed  in  rapidly 
proliferating malignant cells during DNA synthesis. 
Clinical studies on the integration of PET in target 
volume  definition  in  radiotherapy  for  lung,  head  and 
neck, genitourinary and brain tumours were performed. 
FDG-PET  has  a  significant  impact  on  GTV  and  PTV 
delineation  in  lung  cancer.  It  can  detect  lymph  node 
involvement  and  differentiate  malignant  tissue  from 
atelectasis. In head and neck cancer, the value of FDG-
PET  is  still  under  investigation.  FDG-PET  could  be 
superior to CT and MRI in the detection of lymph node 
metastases  and  unknown  primary  cancer,  and  in  the 
differentiation  of  viable  tumour  tissue  after  treatment. 
Therefore,  FDG-PET  might  play  an  important  role  in 
GTV  definition  and  sparing  of  normal  tissue.  The 
imaging  of  hypoxia,  cell  proliferation,  angiogenesis, 
apoptosis and gene expression leads to the identification 
of different areas of a biologically heterogeneous tumour 
mass  that  can  be  individually  targeted  using  intensity 
modulated radiotherapy (IMRT). A higher radiation dose 
may be delivered to an area with tumour hypoxia using 
IMRT. Grosu et al [27] concluded from their study that 
PET may be useful in three important aspects: locating N. Chawapun. Biomed Imaging Interv J 2006; 2(1):e22    7 
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the tumour and tumour margins for radiation treatment 
planning;  identifying  the  biological  properties  of  the 
tumour  visualised  by  PET  for  optimal  treatment;  and 
evaluating the tumour response to therapy. In fact, the 
role  of  PET  in  monitoring  therapy  has  been  reviewed 
[29,30]. PET imaging allows the assessment of patients’ 
responses to a particular therapy early in the course of 
treatment.  However,  the  limitation  of  FDG-PET  in 
differentiation  between  responders  and  non-responders 
has  been  brought  up.  Further  studies  to  define  the 
generally accepted cutoff values are necessary. 
COMPUTER SIMULATION OF TUMOUR RESPONSE TO 
RADIOTHERAPY 
In the past decade, much effort has been made in the 
computer simulation model  to help understand tumour 
growth and response to radiation therapy for optimising 
treatment  planning.  The  In  Silico  Oncology  Group  in 
Greece  [31-34]  presented  a  model  which  is  based  on 
tumour  imaging,  histopathological  and  genetic  data  of 
patients  as  well  as  fundamental  biological  mechanism, 
i.e.,  tumour  growth  kinetics,  and  the  linear  quadratic 
model  of  cell  killing  by  irradiation.  The  software  was 
tested for validation by comparing the model prediction 
with  clinical  data  before,  during  and  after  the 
radiotherapy  course.  The  simulation  results  of 
glioblastoma  multiforme,  using  different  fractionated 
irradiation  schemes,  were  compared  in  patients  with 
different  expression  of  insulin-like  growth  factor 
(overexpression  vs.  lower  expression)  and  different 
status  of  the  p53  gene  (wild  type  vs.  mutant).  The 
simulation  results  were  in  accordance  with  the 
established  clinical  experience:  tumours  with 
overexpression of insulin-like growth factor were more 
radiosensitive.  They  also  revealed  that  the  trend  for 
reduction in the number of surviving tumour cells during 
all schedules of radiotherapy was pronounced in the case 
of  the  tumour  with  wild  type  p53,  which  was  more 
radiosensitive  compared  with  the  tumour  with  mutant 
p53. The model could qualitatively represent the clinical 
reality and produce biologically reasonable results. The 
adaptation of the simulation model to real clinical data to 
improve its clinical reliability is underway. The reality of 
the  model  depends  on  the  input  parameters,  i.e., 
biological  information  of  the  patient,  genetic  profiles, 
and quality of the imaging system. 
CONCLUSIONS 
Molecular  biology  is  the  key  to  individualised 
targeted  cancer  diagnosis  and  treatment.  The  future  of 
radiation oncology lies in exploiting the genetics, or the 
microenvironment  of  the  tumour.  With  genomic  and 
proteomic  studies  as  well  as  bioinformatics,  the 
candidate molecule can be developed. The International 
Atomic  Energy  Agency  (IAEA)  [35]  reported  the 
ongoing  studies  world  wide;  Europe,  the  United 
Kingdom,  Canada,  Japan,  Australia,  and  the  United 
States  aim  to  characterise  the  molecular  profiles  that 
predict normal tissue and tumour radioresponse. Among 
those,  the  GENEPI  project  (genetic  pathways  for  the 
prediction of the effects of irradiation) launched by the 
European  Society  for  Therapeutic  Radiology  and 
Oncology (ESTRO), is the most comprehensive one. In 
this  study,  the  established  tissue  bank  is  linked  to  a 
detailed clinical outcome-database of patients receiving 
radiotherapy, both on normal tissue reactions and tumour 
responses, including accurate dosimetry and follow-up. 
This  is  a  valuable  resource  for  genetic  research  on 
radiation responses. 
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